GLP-1 Providers for Menopause Weight Gain: 9 Verified Picks (2026)

By WPG Research Team · Published · Last verified:

Independent comparison resource for GLP-1 telehealth providers. We may earn affiliate commissions from Eden, Ro, MEDVi, SHED, and Hers. Alloy, Midi, Evernow, and Sesame are not affiliates. Partnership does not change our editorial recommendations. Not personal medical advice.

GLP-1 providers for menopause weight gain — 9 verified picks for 2026 including FDA-approved and compounded options

The short answer (read this first)

The best GLP-1 providers for menopause weight gain in 2026 split three ways. For a clean cash-pay path that carries both FDA-approved (Wegovy, Zepbound, Foundayo) and compounded options under one roof, Eden is the strongest broad pick — no membership fee and transparent pricing starting as low as $129 for the first month on a 3-month compounded semaglutide plan. For FDA-approved medication with insurance help, Ro runs one of the broadest FDA-approved GLP-1 formularies on the market, with a free insurance coverage checker and prior-auth concierge starting at $39/month.

One thing to know up top: compounded GLP-1 medications are not FDA-approved. If you want FDA-approved medication only, start with Ro, Hers, Sesame, or Alloy's branded options. We separate the two paths clearly throughout this page.

See Eden's cash-pay GLP-1 pricing Run Ro's free insurance checker
Not sure yet? Take the 60-second menopause GLP-1 path finder

Quick-Pick Verdict Table

If this sounds like youStart hereWhy
"I want broad cash-pay access with FDA-approved options on the menu"EdenNo membership fee, FDA-approved + compounded, HSA/FSA on branded
"I want FDA-approved Wegovy, Zepbound, or Foundayo with insurance help"RoFree GLP-1 Insurance Coverage Checker, prior-auth concierge, $39 first month
"I want HRT and a GLP-1 from one menopause-trained clinic"Alloy or MidiMenopause-specialty intake, HRT-aware
"I'm cash-paying and want one of the broader compounded menus"MEDVi (see FDA warning letter below)Compounded semaglutide from $179 first month
"I can't or won't inject myself"SHEDDrops, lozenges, and oral options from $199/month
"I want a familiar women's brand with FDA-approved meds"HersBroad FDA-approved formulary post Novo Nordisk partnership
"I'm not sure yet"Free 60-second matchSkip the guessing

Why Does Menopause Weight Gain Hit So Differently?

The short version

During the menopause transition, up to 70% of women gain weight — usually 1–2 pounds per year, roughly 12 pounds across the perimenopause-to-postmenopause window. The reasons are biological, not behavioral: falling estrogen moves fat from hips and thighs to the belly, daily energy use drops about 9%, muscle disappears faster, and sleep often falls apart.

If you're frustrated, that's the right reaction. You're not eating more. You're not lazy. Your body is operating under different rules now.

Estrogen drops, and fat redistributes

Lower estrogen pushes fat storage from your hips and thighs to your abdomen. That belly fat is visceral fat — the deep fat that surrounds your organs — and it's metabolically active. It raises inflammation, blood pressure, and cardiovascular risk.

Your engine runs slower

Research published in the Menopause journal shows total 24-hour energy expenditure drops about 9% through the transition. Spontaneous physical activity energy expenditure — the calories you burn just fidgeting and being alive — drops roughly 30%.

Muscle starts leaking

Estrogen helps maintain muscle. Without it, you lose lean mass faster (sarcopenia). Less muscle means less calorie burn, less strength, and a higher fall risk later.

Sleep collapses, and so does appetite control

Vasomotor symptoms (hot flashes and night sweats) wreck sleep. Bad sleep raises ghrelin (the hunger hormone) and lowers leptin (the fullness hormone). You're hungrier and less satisfied, on a body that already needs fewer calories.

This is why "just eat less and move more" advice fails midlife women. The math changed. If you've been told for years that this was your fault — it wasn't. You just needed a different tool.

Do GLP-1 Medications Actually Work for Menopause Weight Gain?

Short answer: Yes

A NewYork-Presbyterian / Weill Cornell secondary analysis of the SURMOUNT tirzepatide trials, plus Novo Nordisk's STEP UP post-hoc data presented at the European Congress on Obesity in May 2026, both show GLP-1 medications produce similar weight loss in perimenopausal and postmenopausal women as in younger women. Real-world averages run 10–21% body weight loss across 12–18 months. The menopause transition itself doesn't blunt the medication.

SURMOUNT secondary analysis (NewYork-Presbyterian / Weill Cornell Medicine)

Researchers looked at tirzepatide data across premenopausal, perimenopausal, and postmenopausal women. Tirzepatide produced significant reductions in body weight, waist circumference, and waist-to-height ratio at every reproductive stage. It works whether you're 35 or 55.

STEP UP post-hoc analysis (Novo Nordisk, European Congress on Obesity, May 12, 2026)

Semaglutide 2.4 mg and 7.2 mg produced consistent weight loss across all menopause stages — pre, peri, post. Independent of menopausal status.

Real-world averages

People on semaglutide lose about 15% of body weight by 68 weeks in clinical trials (around 30 pounds for a 200-pound starting weight). Tirzepatide users can lose 20% or more. Real-world averages run slightly lower than trials because adherence varies, but the effect is reliable.

One important caveat

GLP-1s don't treat hot flashes, night sweats, vaginal dryness, or estrogen-related sleep collapse. They aren't hormone therapy. They're appetite and metabolic medications. If menopause symptoms are your main problem, you need menopause hormone therapy (or non-hormonal options like Veozah). If weight is your main problem, you need a GLP-1. Many women need both.

Can You Take a GLP-1 and HRT Together?

Short answer: Many women do — and the data is striking

In a January 2026 Mayo Clinic study published in The Lancet Obstetrics, Gynaecology & Women's Health, postmenopausal women taking tirzepatide alongside menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone. A 2024 Mayo Clinic study found a similar pattern with semaglutide. The study can't prove HRT causes better weight loss — that would require a randomized trial — but the magnitude is large enough that, if HRT is medically appropriate for you, stacking both is a defensible move.

Why the combination probably works

The honest caveat: Mayo's own authors noted that women who chose HRT may have already been healthier and more engaged with their care, which could explain some of the difference. This is observational data, not randomized. The data trends consistently across two Mayo Clinic studies — so if HRT is medically appropriate for you, stacking both is defensible. If HRT isn't right for you, the GLP-1 alone still works.
Want a clinic that prescribes both? See Alloy's menopause + GLP-1 program (not an affiliate)
Prefer insurance help for FDA-approved Wegovy or Zepbound? Run Ro's free coverage checker

The Menopause GLP-1 Provider Fit Matrix

Short answer

We compared 9 telehealth GLP-1 providers on 8 menopause-specific criteria. Eden ranks highest for most cash-paying women because it offers FDA-approved Wegovy/Zepbound and compounded options with no membership fee. Ro wins for insurance and brand-name preference. Alloy and Midi win for menopause-specialty care with HRT integration.

Scoring rubric

CriterionWeightWhy it matters in menopause
Menopause / HRT fit25%The HRT + GLP-1 combination is the 2026 weight-loss story
Medication-path clarity (FDA-approved vs compounded)20%After the 2026 FDA actions, this matters more than ever
Cost transparency15%Hidden fees and dose-tier escalation hurt long-term adherence
Body-composition support (muscle, bone)10%Menopausal women lose muscle faster; GLP-1s can worsen this
Regulatory standing10%Verified against FDA enforcement records
Insurance / prior-auth support10%Brand-name GLP-1s are expensive without coverage
State availability5%Compounded options excluded in several states
Cancellation transparency5%Subscription friction is a real cost

The full comparison

Provider-stated pricing and offerings verified directly from each provider's public pages on . Re-verify at checkout before applying — provider terms change.

ProviderMenopause/HRT fitMedication pathFirst-month priceOngoingMembershipInsurance supportState limitsRegulatory note
EdenGeneral weight intakeFDA-approved (Wegovy, Zepbound, Ozempic, Mounjaro) + compounded sema/tirz$129 on 3-mo compounded sema plan$249/mo (compounded sema, post-promo)NoneHSA/FSA on branded; not insurance-firstCompounded varies by stateNot named in March 3, 2026 FDA action
RoGeneral obesity intakeFDA-approved: Foundayo pill, Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, Ozempic$39 first month membership$149/mo or as low as $74/mo annual; medication separateRequiredFree GLP-1 Insurance Coverage Checker + PA conciergeAvailable nationallyNot named in March 3, 2026 FDA action
MEDViNo menopause-specific intakeCompounded sema/tirz (injection + oral)$179 (compounded sema first month)$299/mo (compounded sema refills)NoneNot insurance-firstVaries⚠️ FDA warning letter #721455 dated Feb 20, 2026
SHEDNo menopause-specific intakeCompounded injections + drops + lozenges + oral; FDA-approved listedFrom $199/mo (lozenges)$199–$399/mo by formatProgram-dependentNot insurance-firstVariesNot named in March 3, 2026 action
HersWomen-coded brand, not menopause-specializedFDA-approved Wegovy pill, Wegovy pen, Ozempic, Zepbound vial, Zepbound KwikPen, Foundayo, Mounjaro$39 first month membership$149/mo; medication separateRequiredBrand-medication pathNationalWound down compounded GLP-1 advertising March 2026
Alloy★★★ Menopause-trained cliniciansFDA-approved (Zepbound, Wegovy, Foundayo) + compounded sema, tirz, liraglutide$99/mo membership; compounded sema from $70$99/mo membership + medicationRequiredNot insurance-firstCompounded unavailable in AL, AR, CA, NV, LA, MS, DCNot named in March 3, 2026 action
Midi★★★ Menopause + HRT specialtyCompounded GLP-1 + brand-name access via clinician$250 self-pay or insured$150 follow-up; medication separateNoneMany PPO plans; not Medicaid/Medi-Cal/MedicareAll 50 statesNot named in March 3, 2026 action
Evernow★★ Menopause + HRT platformGLP-1 access + HRTVaries ($29–$49/mo seen)Plan-dependent; medication separateRequiredFSA/HSAVariesNot named in March 3, 2026 action
SesameGeneral care, not menopause-specificFDA-approved: Wegovy pill, Wegovy pen, Zepbound vial, Zepbound KwikPen, Foundayo, Ozempic$59/mo annual subscription$59/mo annual; medications from $149/mo cash-payRequiredPA assistance; Costco-member pricingAvailable nationallyNot named in March 3, 2026 action

Sources: tryeden.com, ro.co, home.medvi.org, tryshed.com, forhers.com, myalloy.com, joinmidi.com, evernow.com, sesamecare.com, and FDA enforcement records — all accessed .

Not sure which path fits you?

Four questions. One personalized recommendation. No email gate.

Get my personalized GLP-1 menopause match

Provider Deep Dives — Who Each One Is Actually For

Eden

Best broad cash-pay path

Best broad cash-pay path with FDA-approved and compounded options

The punchline

Eden is the cleanest broad cash-pay GLP-1 provider for menopausal women in 2026. It carries FDA-approved Wegovy, Zepbound, Ozempic, and Mounjaro at branded pricing alongside compounded semaglutide and tirzepatide. There's no membership fee, free initial consultation, and HSA/FSA works on branded medications.

What we verified (May 13, 2026):

  • Compounded semaglutide as low as $129 for the first month on a 3-month plan, $249/month ongoing (verify current offer at tryeden.com)
  • FDA-approved Wegovy, Zepbound, Ozempic, and Mounjaro available at branded pricing
  • No membership fee, free initial consultation
  • LegitScript-certified pharmacy partners
  • Eden's own published member data: members self-reported losing an average of 29.3 pounds in the first six months (111 members on GLP-1 injections, per Eden's public weight-loss page)
  • HSA/FSA accepted on branded medications
  • Compounded options explicitly disclosed as not FDA-approved on Eden's pages

Who Eden is best for:

  • Women already managing menopause care elsewhere (OB-GYN, primary care, menopause specialist) who want a clean GLP-1 path
  • Cash-paying women who want both FDA-approved and compounded options without jumping providers
  • Women who hate subscription bloat — no membership, no app, no mandatory coaching layer

The honest tradeoff

Eden is not a menopause-specialist provider. The intake isn't built for vasomotor symptoms, sleep collapse, or HRT coordination. If you need a clinician who'll evaluate your hot flashes, your night sweats, and your weight together — and prescribe HRT in the same visit — Eden isn't that. Alloy or Midi is. But because Eden skips the menopause-specialty positioning, it can offer FDA-approved Wegovy and Zepbound and compounded options at transparent prices with no membership fee. For the woman whose menopause symptoms are already managed and whose actual problem is weight, that's the right trade.
See Eden's current GLP-1 pricing

Ro

Best for FDA-approved + insurance

Best for FDA-approved Wegovy, Zepbound, Foundayo, and insurance help

The punchline

Ro carries one of the broadest FDA-approved GLP-1 formularies on the market — Foundayo (orforglipron, the new FDA-approved oral GLP-1), Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, and Ozempic — with a free GLP-1 Insurance Coverage Checker and an insurance concierge that handles prior-authorization paperwork. Membership starts at $39 for the first month.

What we verified (May 13, 2026):

  • Ro Body membership: $39 for the first month, $149/month ongoing, or as low as $74/month with annual plan paid upfront
  • FDA-approved formulary: Foundayo pill, Wegovy pill, Wegovy pen, Zepbound pen, Zepbound KwikPen, and Ozempic
  • Ozempic is FDA-approved for type 2 diabetes; weight-loss use may be off-label when clinically appropriate
  • Medication pricing matched to LillyDirect, NovoCare, and TrumpRx
  • Free GLP-1 Insurance Coverage Checker available without account creation
  • Insurance concierge handles prior-authorization submissions
  • Available in all 50 states

The honest tradeoff

Ro isn't menopause-specialized. Ro Body is built around general obesity care, not midlife women specifically. If your priority is a menopause-trained clinician who'll consider HRT in the same visit, Alloy or Midi will feel more tailored. But if your priority is "what's the most reliable path to FDA-approved Wegovy, Zepbound, or Foundayo at the best possible price including insurance help," Ro is the strongest choice.
Run Ro's free insurance coverage checker Get started with Ro for $39

Alloy

Best menopause-specialty(not an affiliate)

Best menopause-specialist clinic if HRT and GLP-1 from one provider matters

The punchline

Alloy is the closest thing to a menopause-specialty GLP-1 clinic on the market. Menopause-trained clinicians, HRT-aware intake, both FDA-approved and compounded options listed, transparent $99/month membership. If your top priority is one provider who'll handle hormones and weight together, Alloy is the right call.

What we verified (May 13, 2026):

  • $99/month Alloy Weight Care membership
  • FDA-approved options: Zepbound, Zepbound KwikPen, Wegovy pen, Wegovy pill, Foundayo pill
  • Compounded options: compounded semaglutide (from $70), tirzepatide, liraglutide
  • Menopause-trained clinicians, HRT prescribed in-house
  • Compounded options unavailable in AL, AR, CA, NV, LA, MS, or DC
  • FDA-approved Zepbound and Wegovy unavailable in MS and LA

The tradeoff

Alloy's $99/month membership is on top of medication cost. Eden, MEDVi, and SHED don't charge a separate membership for their core compounded programs. If you don't need menopause-specialty care, you're paying for something you won't use. We don't earn a commission from Alloy — we're naming it because for the reader who specifically needs menopause-aware care, sending you to Eden would be the wrong recommendation.
See Alloy's GLP-1 Weight Care program

Midi Health

Best for insured menopause care(not an affiliate)

Best for insurance-covered menopause care with GLP-1 access

The punchline

Midi accepts many insurance plans, employs menopause-trained clinicians in all 50 states, and offers GLP-1 prescriptions (including compounded options) alongside HRT, labs, and full menopause care. If your insurance covers the visits, this is the lowest out-of-pocket path to menopause-aware weight care.

What we verified (May 13, 2026):

  • In-network with many PPO plans
  • Not covered by Medicare or Medicare-related plans, Medicaid, or Medi-Cal
  • Self-pay rates: initial visit $250, follow-up visits $150
  • Compounded GLP-1 listed from $127.90/month + refrigerated shipping
  • Menopause-trained clinicians, HRT prescribed
  • Available nationally (all 50 states)
  • Trustpilot rating around 4 stars from over 1,200 reviews
"I've struggled with menopausal weight gain. My Midi clinician helped address this and more, I felt heard and validated." — Patient testimonial published by Midi Health (joinmidi.com)

The tradeoff

Some Trustpilot reviews flag inconsistent clinician quality and follow-through. Midi has a wider clinician roster than a single-doctor practice, so individual experience varies. If you want a single named menopause clinic with consistent protocols, Alloy may feel more uniform.
See Midi's pricing and insurance acceptance

MEDVi

One regulatory note to know

One of the broader compounded menus — with an FDA warning letter you should know about

The punchline

MEDVi runs one of the broader compounded GLP-1 menus — compounded semaglutide and tirzepatide injectables plus oral options — at the lowest verified starting price among compounded providers ($179 for the first month of compounded semaglutide). MEDVi also received FDA warning letter #721455 on February 20, 2026 addressing marketing claims. We're telling you because you'd want to know.

What we verified (May 13, 2026):

  • Compounded semaglutide injections: $179 first month, $299 refills
  • Compounded tirzepatide and oral formulations listed (re-verify current pricing at checkout)
  • No membership fee, no contract
  • LegitScript certified
  • ~13,000 Trustpilot reviews with TrustScore around 4.5; recent reviews include both positive feedback and billing/fulfillment complaints

FDA Warning Letter #721455 — February 20, 2026

MEDVi's warning letter alleged that the company's marketing made false or misleading representations — including claims implying compounded products are equivalent to FDA-approved medications and language that obscured product sourcing — and that the products were therefore misbranded. The letter wasn't a direct finding that medication shipped to patients failed quality testing. But "misbranding" is a serious regulatory finding, and the FDA's broader 2026 enforcement sequence makes clear the compounded GLP-1 market is in active transition.

Who should pick a different provider

If regulatory clarity is your top concern, choose Eden (compounded plus FDA-approved with a cleaner enforcement record) or Ro (FDA-approved only). We don't bury this. Competitor pages often do.
See MEDVi's compounded GLP-1 menu

SHED

Best for needle-averse

Best for needle-averse women who want oral, sublingual, drops, or lozenges

The punchline

SHED specializes in compounded GLP-1 formulations that don't require weekly injections. If "I'm not poking myself in the stomach every week" is a dealbreaker, SHED is the option built around you. It also lists FDA-approved options including Foundayo, Wegovy, and Zepbound.

What we verified (May 13, 2026):

  • Compounded semaglutide injections from $299/month
  • Compounded tirzepatide injections from $399/month
  • GLP-1 liquid drops from $229/month
  • Lozenges from $199/month
  • Oral semaglutide liposomal tablets available
  • FDA-approved options listed: Foundayo, Wegovy, Zepbound
  • Pricing varies by product/page on SHED's site — re-verify at checkout

The honest tradeoff

Compounded oral, sublingual, and drop GLP-1 absorption is not equivalent to injectable absorption. The compounded non-injectable approach is a tradeoff — better tolerance for needle-averse women, less predictable pharmacology than injectables. If FDA-approved oral matters most, SHED's Foundayo route is legitimate, but Ro's broader insurance support makes it the better default for that specific need.
See SHED's GLP-1 options

Hers

Familiar women's brand

Best familiar women's brand with FDA-approved meds

Hers is the right pick if you specifically want a familiar women's telehealth brand and FDA-approved GLP-1 medication. Following Hims & Hers' March 2026 strategic partnership with Novo Nordisk and the company's shift away from advertising compounded GLP-1 alternatives, Hers now lists a broad FDA-approved GLP-1 formulary on a women-coded platform that also handles HRT and other women's health care.

  • FDA-approved: Wegovy pill, Wegovy pen, Ozempic, Zepbound vial, Zepbound KwikPen, Foundayo pill, and Mounjaro
  • Membership pricing: $39 first month, then $149/month; medication cost is separate
  • Hims & Hers announced in March 2026 it would no longer advertise compounded GLP-1 offerings in most circumstances after entering the Novo Nordisk partnership
  • HRT and other women's health care available separately on the Hers platform

The tradeoff

Hers isn't menopause-specialized in the way Alloy or Midi are — it's a women's general telehealth brand. If you want a menopause-trained clinician evaluating your hormone profile, choose Alloy or Midi. If you want a familiar consumer-brand experience with FDA-approved medication, Hers fits.
See Hers' weight-loss program

Evernow

(not an affiliate)

Menopause platform with HRT and GLP-1 access

Evernow is a menopause-focused platform offering HRT, weight care, and GLP-1 access under one membership (current public pages show pricing ranging from $29/month annual plan to $49/month, depending on the landing page; verify on the live page before signing up — medication is separate). Good fit if you want menopause care as the primary product and a GLP-1 as a secondary path. We don't earn a commission from Evernow; we're naming it because it's a legitimate option for the right reader.

See Evernow

Sesame

Provider-choice marketplace with FDA-approved branded GLP-1s

Sesame is a provider-choice marketplace ($59/month with annual subscription, medication separate) that lists FDA-approved GLP-1s including Wegovy pill, Wegovy pen, Zepbound vial, Zepbound KwikPen, Foundayo, and Ozempic. Cash-pay GLP-1 medication pricing starts as low as $149/month per Sesame's current page. Strong option if you want to pick your specific clinician and need PA assistance. Costco-member pricing applies on certain medications. Less menopause-specific than Alloy or Midi.

See Sesame's GLP-1 program

FDA-Approved vs Compounded GLP-1: What Changed in 2026

Short answer

The FDA spent the first half of 2026 reshaping how compounded GLP-1 medications are marketed and supplied. Compounded GLP-1s remain available through patient-specific compounding under specific conditions, but the market is in active transition — and "compounded vs FDA-approved" is now a more important question than it was a year ago.

The 2026 regulatory timeline

DateAction
FDA announces intent to act against non-FDA-approved compounded GLP-1s, including restricting APIs
Date on MEDVi's individual warning letter (#721455)
FDA publicly announces warning letters issued to more than 30 telehealth companies marketing compounded GLP-1s
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list

Choose FDA-approved if…

  • You're risk-averse about regulatory status
  • You have insurance that may cover part of the cost
  • You want documented sourcing, manufacturing, and supply chain
  • Cost isn't your primary constraint

Start with:

RoHers

Choose compounded if…

  • Cost is your primary constraint
  • You've accepted that compounded medications are not FDA-approved or FDA-reviewed for safety, effectiveness, or quality
  • You want lower starting prices and no membership friction

Start with:

EdenMEDVi (FDA letter disclosed above)

Choose menopause-specialty care if…

Start with Alloy or Midi

One compliance line we hold ourselves to: We will not tell you compounded semaglutide is the same as Wegovy. They are not the same medication. Wegovy is an FDA-approved branded product manufactured by Novo Nordisk under FDA oversight. Compounded semaglutide is prepared by a compounding pharmacy and is not FDA-approved or FDA-reviewed for safety, effectiveness, or quality. If a provider's marketing tells you the two are equivalent, that's a red flag.
FDA-approved priority? Run Ro's free coverage checker Cash-pay compounded? See Eden's pricing

Will You Lose Muscle on a GLP-1 During Menopause?

Short answer: Partly, yes

Across GLP-1 studies in general populations, lean body mass can account for roughly 25–40% of total weight lost. Menopausal women — who are already losing muscle faster because of falling estrogen — face this risk in compounded form. The fix is adequate protein, resistance training at least 2–3 days a week, and choosing a provider who proactively talks about it.

If you lose 30 pounds and 10 of those pounds are muscle, you'll feel weaker, more tired, and more frail in five years than someone who lost 30 pounds of mostly fat. The scale won't show it. Your body composition will.

What to ask any provider before starting

Why the lowest effective dose matters in menopause: Some clinicians prefer staying at lower GLP-1 doses to limit nausea-driven undereating and protect protein intake. Less appetite suppression means easier protein intake, which means more muscle preservation. Bone density matters too. Postmenopausal osteoporosis risk is real. Calcium, vitamin D, and resistance training aren't optional during menopause — they're standard care.

What Does This Actually Cost?

Short answer

The advertised first-month price isn't what you'll actually pay long-term. Compounded semaglutide programs range from roughly $179 to $299/month ongoing. Compounded tirzepatide runs $299–$499/month. FDA-approved Wegovy, Zepbound, and Foundayo through Ro start at $39 for the first-month membership, then $149/month or as low as $74/month with annual prepay — plus medication cost. Insurance can change all of this dramatically.

The real monthly cost formula:

Medication + membership/program fee + shipping + labs + insurance copay or cash-pay price + dose-increase changes + cancellation friction = your actual cost

Compounded ongoing prices (cash-pay):

ProviderOngoing
Eden compounded sema$249/mo (after 3-mo intro)
MEDVi compounded sema$299/mo refills
SHED compounded sema$299/mo
SHED lozenges$199/mo
SHED drops$229/mo
Alloy compounded sema~$169/mo ($70 med + $99 membership)

FDA-approved (membership + separate medication):

ProviderMembership
Ro$39 first mo → $149/mo (or $74/mo annual); med separate
Hers$39 first mo → $149/mo; med separate
Sesame$59/mo annual; meds from $149/mo

Insurance reality check

Coverage for weight-loss GLP-1s varies dramatically by plan. Some plans cover Wegovy and Zepbound with prior authorization. Many still don't cover them for weight loss alone. Medicare update: Medicare Part D generally doesn't cover GLP-1s for weight loss today, but per CMS, eligible Part D beneficiaries are expected to access certain GLP-1 drugs through the Medicare GLP-1 Bridge from July 1, 2026 through December 31, 2027, with prior-authorization criteria. Medicaid participation under the BALANCE model can begin as early as May 2026, depending on state and manufacturer participation. HSA/FSA: Branded FDA-approved GLP-1s prescribed for a medical condition are typically HSA/FSA eligible. Compounded medications are usually eligible too when prescribed. Verify with your plan administrator.
Run Ro's GLP-1 Insurance Coverage Checker (free)

Who Should NOT Start with an Online GLP-1 Provider

Short answer

If you have a personal or family history of medullary thyroid cancer or MEN2, a history of pancreatitis, are pregnant or trying to conceive, take an aromatase inhibitor for breast cancer history, or have complex diabetes with multiple medications — start with an in-person clinician before any online provider. These aren't fine-print warnings.

Contraindications (per FDA prescribing information for FDA-approved GLP-1s)

Personal or family history of medullary thyroid carcinoma

Boxed-warning contraindication on Wegovy, Zepbound, and Foundayo

Multiple endocrine neoplasia syndrome type 2

Boxed-warning contraindication

Serious hypersensitivity reaction to GLP-1 medications

Discussed in FDA prescribing information

Pregnancy or actively trying to conceive

Labels advise discontinuing weight-loss GLP-1s when pregnancy is recognized. Weight loss offers no benefit during pregnancy and may cause fetal harm.

Use extra caution and start with in-person care if…

Menopause-specific safety considerations

Oral medications and gastric emptying

GLP-1 medications can delay how fast your stomach empties. This can affect the absorption of oral medications — including oral progesterone or any other oral medication that matters for symptom control or safety. Ask your prescriber about timing and monitoring.

Bone density

If you've had a recent DEXA scan, bring it to your provider. Postmenopausal osteoporosis risk plus GLP-1-related lean mass loss is a stack to monitor.

Vasomotor symptoms

GLP-1 medications don't treat hot flashes. If hot flashes are wrecking your sleep, address that separately with HRT or non-hormonal options.

What Real Women on GLP-1 During Menopause Are Saying

We only cite real, attributable quotes from public sources — no invented testimonials. Per FTC and FDA guidelines on testimonials: individual results vary. Testimonials aren't medical evidence.

"I've struggled with menopausal weight gain. My Midi clinician helped address this and more, I felt heard and validated."

— Patient testimonial published by Midi Health (joinmidi.com)

"HRT helped everything EXCEPT my weight. Took GLP-1 to do that."

— Anonymous Reddit user, r/compoundedtirzepatide

"After 27 years of yo-yo dieting, this medication has finally helped me lose weight and get healthy."

— Kimberly DelRosso, age 57, in AARP feature on weight-loss medications (Wegovy user; reported 50-pound weight loss and normalized A1c, blood pressure, and resolution of sleep apnea)

Our Methodology

Short answer

We compared 9 telehealth GLP-1 providers (5 affiliate partners, 4 non-affiliates) on 8 menopause-specific criteria. We pulled pricing, medication paths, insurance support, state availability, and regulatory status directly from each provider's website on , cross-referenced against FDA enforcement records, DailyMed prescribing information, CMS, Mayo Clinic newsroom reporting, and peer-reviewed obesity literature. Affiliate economics did not override regulatory status or reader fit.

What we verified on :

Eden: pricing, FDA-approved option availability, LegitScript certification, HSA/FSA, self-reported member data (29.3 lb average / 6 months / 111 members) — verified at tryeden.com
Ro: $39 first month / $149 ongoing / as low as $74 annual prepay, full FDA-approved formulary, free coverage checker, insurance concierge — verified at ro.co
MEDVi: $179 first month / $299 refills for compounded semaglutide, FDA warning letter #721455 dated February 20, 2026 — verified at home.medvi.org and FDA enforcement records
SHED: semaglutide $299/mo, tirzepatide $399/mo, drops $229/mo, lozenges $199/mo, FDA-approved options listed — verified at tryshed.com
Hers: full FDA-approved formulary, $39/$149 membership, March 2026 Novo Nordisk partnership — verified at forhers.com
Alloy: $99/month membership, compounded sema from $70, state exclusions — verified at myalloy.com
Midi: insurance acceptance, self-pay rates, compounded GLP-1 from $127.90, all 50 states — verified at joinmidi.com
Evernow: $29–$49/month membership, menopause + GLP-1 platform — verified at evernow.com
Sesame: $59/month annual, broad FDA-approved formulary, medications from $149/mo — verified at sesamecare.com

Medical and regulatory sources:

Affiliate disclosure: Eden, Ro, MEDVi, SHED, and Hers are affiliate partners. Alloy, Midi, Evernow, and Sesame are not. Partnership doesn't change our editorial picks. We name non-partners when they're a better fit for the reader. How we update: Pricing and offering pages are re-verified monthly. Regulatory status is re-verified whenever the FDA publishes new GLP-1 enforcement guidance. Last full review: .

Related guides

Frequently Asked Questions

Yes. The 2026 evidence — Novo Nordisk's STEP UP post-hoc analysis at ECO 2026 and the NewYork-Presbyterian / Weill Cornell SURMOUNT secondary analysis — shows GLP-1s produce similar weight loss in perimenopausal and postmenopausal women as in younger women. Real-world averages run 10–21% body weight loss over 12–18 months.

For most women, tirzepatide produces more weight loss than semaglutide on average (20%+ vs ~15% in clinical trials). But the right choice depends on your tolerance, insurance, cost, and your clinician's judgment. Don't choose based on average weight-loss headlines alone. See the provider deep dives for which medication each provider carries.

For most cash-paying women: Eden (broad path, FDA-approved + compounded, no membership). For insurance and FDA-approved meds: Ro. For menopause-specialty care with HRT: Alloy or Midi. The full Provider Fit Matrix breaks it down by reader profile.

Many women do, and Mayo Clinic's January 2026 study found women on tirzepatide plus HRT lost 35% more weight than women on tirzepatide alone. The combination should be discussed with a clinician. Alloy, Midi, and Evernow prescribe both in-house.

Compounded GLP-1 medications remain available through patient-specific compounding under specific conditions. They are not FDA-approved or FDA-reviewed for safety, effectiveness, or quality. The FDA has warned about misleading marketing claims and fraudulent products in this market. Choose a provider that discloses what they're prescribing clearly.

Partly, yes. Across studies in general populations, lean body mass can account for 25–40% of total weight lost on GLP-1 therapy. Menopausal women already lose muscle faster from falling estrogen, so the risk compounds. The fix is adequate protein, resistance training 2–3 times per week, and not chasing the highest tolerable dose.

Clinical trial averages: about 15% of body weight on semaglutide (Wegovy) over 68 weeks; about 20%+ on tirzepatide (Zepbound). Real-world averages are slightly lower because adherence varies. Novo Nordisk's STEP UP data shows results are similar whether you're premenopausal or postmenopausal.

In the STEP 1 extension trial, participants regained about two-thirds of their semaglutide-related weight loss within one year of stopping the medication and the structured lifestyle program. This is why provider-supported maintenance planning matters. Ask before you start: what's the plan if you reach your goal, or if you need to stop?

Coverage varies dramatically by plan. Some plans cover Wegovy or Zepbound with prior authorization; many don't cover weight-loss GLP-1s at all. Medicare Part D doesn't currently cover GLP-1s for weight loss, but the Medicare GLP-1 Bridge is expected to provide access for eligible beneficiaries from July 1, 2026 through December 31, 2027.

No. GLP-1s are not hormone therapy. They don't treat vasomotor symptoms, vaginal dryness, or estrogen-related sleep changes. If those are your main problems, you need menopause hormone therapy or non-hormonal options. Many women take both.

Foundayo is the FDA-approved oral GLP-1 from Eli Lilly, approved in 2026 for weight reduction in eligible adults. Available through Ro, Hers, Sesame, Alloy, and SHED. Don't confuse it with compounded oral semaglutide — they're different medications with different regulatory status.

Usually yes for FDA-approved GLP-1s prescribed for a medical condition. Often yes for compounded medications too when prescribed. Verify with your plan administrator. Eden and Hers explicitly call out HSA/FSA eligibility on branded options.

Yes, this is increasingly common after the 2026 FDA enforcement sequence. Ro and Hers are the strongest paths for the transition because they handle FDA-approved meds plus (in Ro's case) insurance coverage checks.

Still not sure which GLP-1 program is right for you?

Take our free 60-second matching quiz. We'll ask about menopause stage, HRT, insurance, budget, medication preference, and state availability — then route you to the provider that actually fits, including the non-affiliates if they're your better answer.

Find my GLP-1 menopause path

The one-minute version (if you've scrolled this far)

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We verify provider pricing, regulatory status, and medication paths before publication, and update our pages monthly. Last verified: . Affiliate disclosure: Eden, Ro, MEDVi, SHED, and Hers are affiliate partners. Alloy, Midi, Evernow, and Sesame are not. Partnership does not affect our editorial recommendations. We are not your doctor. Discuss any medication decision with a licensed clinician who knows your medical history.